USA - engelsk - NLM (National Library of Medicine)

mylan institutional llc - levoleucovorin calcium pentahydrate (unii: wa16a5y52x) (levoleucovorin - unii:990s25980y) - levoleucovorin 10 mg in 1 ml - levoleucovorin injection is contraindicated for patients who have had previous allergic reactions attributed to folic acid or folinic acid. animal reproduction studies have not been conducted with levoleucovorin. it is not known whether levoleucovorin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. levoleucovorin should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from levoleucovorin, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. [see clinical studies (14).] clinical studies of levoleucovorin in the treatment of osteosarcoma did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. in the ncctg clinical trial of levoleucovo

USA - engelsk - NLM (National Library of Medicine)

amneal pharmaceuticals llc - levoleucovorin calcium (unii: 778xl6vbs8) (levoleucovorin - unii:990s25980y) - levoleucovorin 10 mg in 1 ml - levoleucovorin injection is indicated for: - rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. - diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. - the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. limitations of use levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin b12 , because of the risk of progression of neurologic manifestations despite hematologic remission. levoleucovorin injection is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid or folinic acid [see adverse reactions (6.2)] . risk summary there are limited data with levoleucovorin use in pregnant women. animal reproduction studies have not been conducted with levoleucovorin. levoleucovorin is administered in combination with methotrexate or flu

USA - engelsk - NLM (National Library of Medicine)

actavis pharma, inc. - levoleucovorin calcium (unii: 778xl6vbs8) (levoleucovorin - unii:990s25980y) - levoleucovorin 10 mg in 1 ml - levoleucovorin for injection is indicated for: - rescue after high-dose methotrexate therapy in patients with osteosarcoma [see clinical studies ( 14 )] .  - diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination. limitation of use levoleucovorin for injection is not indicated for the treatment of pernicious anemia or megaloblastic anemia secondary to lack of vitamin b12 , because of the risk of progression of neurologic manifestations despite hematologic remission. levoleucovorin is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid, or folinic acid [see adverse reactions ( 6.2 )] . risk summary there are limited data with levoleucovorin use in pregnant women.  animal reproduction studies have not been conducted with levoleucovorin.   levoleucovorin is administered in combination with methotrexate, which can cause embryo-fetal harm.  refer to methotrexate prescribing information for additional inform

USA - engelsk - NLM (National Library of Medicine)

bluepoint laboratories - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin 10 mg in 1 ml - leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - levoleucovorin calcium (unii: 778xl6vbs8) (levoleucovorin - unii:990s25980y) - levoleucovorin 50 mg in 5 ml - levoleucovorin for injection is indicated for: - rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. - diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. - the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. limitations of use levoleucovorin for injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin b12, because of the risk of progression of neurologic manifestations despite hematologic remission. levoleucovorin for injection is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid or folinic acid [see adverse reactions (6.2)] . risk summary there are limited data with levoleucovorin for injection use in pregnant women. animal reproduction studies have not been conducted with levoleucovorin. levoleucovorin is administered in combination

USA - engelsk - NLM (National Library of Medicine)

amneal pharmaceuticals llc - levoleucovorin calcium (unii: 778xl6vbs8) (levoleucovorin - unii:990s25980y) - levoleucovorin 50 mg - levoleucovorin for injection is indicated for: - rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. - diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. - the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. limitations of use levoleucovorin for injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin b12 , because of the risk of progression of neurologic manifestations despite hematologic remission. levoleucovorin for injection is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid or folinic acid [see adverse reactions (6.2)] . risk summary there are limited data with levoleucovorin use in pregnant women. animal reproduction studies have not been conducted with levoleucovorin. levoleucovorin is administered in combination with methotr

USA - engelsk - NLM (National Library of Medicine)

fresenius kabi usa, llc - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin 200 mg in 20 ml - leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma.   leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin 50 mg in 5 ml - leucovorin calcium, usp rescue is indicated after high dose methotrexate therapy in osteosarcoma. leucovorin calcium, usp is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium, usp is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin calcium, usp is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

USA - engelsk - NLM (National Library of Medicine)

sagent pharmaceuticals - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin 50 mg in 5 ml - leucovorin calcium rescue is indicated after high dose methotrexate therapy in osteosarcoma. leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

USA - engelsk - NLM (National Library of Medicine)

teva parenteral medicines, inc. - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin 100 mg in 10 ml - leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. leucovorin calcium is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin calcium is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. leucovorin is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12. a hematologic remission may occur while neurologic manifestations continue to progress.